Dr Sheila Waiter noted that, "while it is generally accepted that the benefits of having Hemofil available for the treatment of bleeding episodes far out-weigh the risk of acquiring hepatitis B nevertheless the statement that 'every lot of this particular product is probably contaminated with hepatitis B virus' will come as a surprise to many clinicians using the product".

Chronology Information

Date:

Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Dr Sheila Waiter